Domain Not Resolving

Content Delivery Network

reCAPTCHA

Cloudflare CDN

reCAPTCHA v2

HSTS IncludeSubdomains PreLoad

ASP.NET Ajax

Getty Images

Google Analytics IP Anonymization

Chief Commercial Officer

Andy Hurley

President and Chief Executive Officer at MiNK Therapeutics

Jennifer Buell

Chief Legal Officer

Robin Abrams

Chief People Officer (CHRO)

Tracy Clemente

VP Finance

Christine Klaskin

VP Molecular and Information Science

Dennis Underwood

Vice President Market Access

Doug Kylander

VP Medical Affairs (The Americas) and Global HEOR

Matt Yousefi

Sr.Director, Process & Manufacturing Sciences

Abdul Wajid

Head of Global Biologics Operations & Site Head

Al Dadson

Brian Corvese

Director

Garo Armen

Chairman & CEO

Jennifer S. Buell

President & Chief Operating Officer

Marc van Dijk

Chief Technology Officer

Robin Taylor

Mark Findeis

Executive Director, Research Biochemistry

United States Companies With More Than 100 Employees (Top 10K)

Greater Boston Area Public Companies With More Than $50M in Revenue

Northeastern US Companies With More Than 100 Employees (Top 10K)

Massachusetts Public Companies With More Than $1M in Revenue

Agenus develops and commercializes immunotherapies and vaccines for cancer and infectious diseases. The company's treatment aims to stimulate the immune system to recognize and fight cancer cells. Its goal is to treat cancers with novel combinations utilizing its unique portfolio of checkpoint antibodies, tumor microenvironment modifiers, vaccines, and adjuvants. In addition to a broad portfolio, the company has an accomplished team of scientists, novel technology platforms, and fully-integrated end-to-end capabilities from discovery to GMP manufacturing.

It was established in 1994 and is headquartered in Lexington, Massachusetts.

Ligand Pharmaceuticals

Post-IPO Debt - Agenus

Post-IPO Equity - Agenus

Lexington

Massachusetts

United States

North America

Agenus

AGEN LAWSUIT ALERT: Levi & Korsinsky Notifies Agenus Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

Agenus Inc. Sued for Securities Law Violations - Contact

Bragar Eagel & Squire, P.C. Reminds Investors That Class

RLF Encourages Agenus Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AGEN

AGENUS INC. (NASDAQ: AGEN) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Agenus Inc. Investors of Upcoming Deadline

Agenus presents data on botensilimab/balstilimab clinical responses

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Agenus Inc. of Class Action Lawsuit and Upcoming Deadlines - AGEN

Agenus to Participate in September Investor Conferences

Agenus welcomes Tom Harrison to its Board of Directors

BMS ducks out of $1.56bn TIGIT alliance with Agenus

Chile

South America

Bangladesh

Asia

India

Pakistan

HTML5

Fonts.com

Starfield SSL

Modernizr

F5 NGINX

Google Compute Engine

Adobe Fonts

Google Fonts

Bootstrap

Google Analytics

Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).

Agenus Inc.

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general	Mar 8, 2024 10:48 PM	0d2e2ee0
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Mar 8, 2024 10:48 PM	374ca18d
company summary	general
signals	general
crunchbase trigger	general	Nov 4, 2024 10:53 AM	d23ba8e2
crunchbase profile	general	Nov 4, 2024 11:19 AM	195a12dd
li profile	general
translate crunchbase fundingrounds	general	Nov 6, 2024 3:12 PM	fa271eec
peers	general
news basic	general	Mar 8, 2024 10:48 PM	ceed9271
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:AGENUSBIO

Agenus Inc.

Last Close

2.86

22/11 21:00

Market Cap

66.82M

Beta: -

Volume Today

1.08M

Avg: -